Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27967417 | 0.79 | TDP1 (0.38) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL2228160 | 0.76 | CYP3A4 (0.41) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL1782525 | 0.71 | ALDH1A1 (0.45) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL5579491 | 0.70 | LMNA (0.53) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL4453197 | 0.69 | LMNA (0.40) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL29102030 | 0.68 | — | — | |
| SCHEMBL27807426 | 0.68 | LMNA (0.36) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL12349896 | 0.67 | LMNA (0.58) | LMNAGLAHSD17B10TDP1ALDH1A1 | |
| SCHEMBL29204149 | 0.67 | HSD17B10 (0.73) | LMNAHSD17B10TDP1ALDH1A1MAPT | |
| SCHEMBL16198389 | 0.67 | LMNA (0.58) | LMNAGLAHSD17B10TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399931-B2 | Octahydroanthracene compound, preparation method and application thereof | SHANDONG XINHUA PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | claimed |
| CN-110092788-A | Substituted [1,2,4] triazol [1,5-a] pyrimidin-7-yl compound as PDE2 inhibitor | 达特神经科学(开曼)有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-106459062-A | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | claimed |
| EP-1638568-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | claimed |
| EP-1638568-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1819721-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | Plant Bioscience Limited (GB) | 2007-08-22 | — | — | EP | claimed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| WO-2006054102-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | PLANT BIOSCIENCE LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| EP-1638568-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-11-24 | — | — | US | claimed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | claimed |
| CN-1147493-C | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof | 3M | 2004-04-28 | — | — | CN | claimed |
| CN-1432606-A | Optical recording medium dye | LAIDE SCI TECH CO LTD (CN) | 2003-07-30 | — | — | CN | claimed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | claimed |
| CN-1320126-A | Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2001-10-31 | — | — | CN | claimed |
| EP-0253711-B1 | 1H,3H-pyrrolo[1,2-c]thiazole derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1990-05-23 | — | — | EP | claimed |
| CN-113454082-B | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-0093376-A2 | 1-Sulfo-2-azetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-09 | — | — | EP | disclosed |
| US-3980089-A | Novel heterocyclic flavoring compositions and processes | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | LMNA 2617/4885GLA 2634/4885HSD17B10 1960/4885 |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | MALT1, BCL6, CD4 | LMNA 3446/4885GLA 2545/4885HSD17B10 3066/4885 |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | LMNA 2116/4885GLA 3177/4885HSD17B10 2571/4885 |
| US-10399931-B2 | Octahydroanthracene compound, preparation method and application thereof | ODC1, OTC, TMT1A | LMNA 2598/4885GLA 2336/4885HSD17B10 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.